key: cord-0772722-3eqrsk81
authors: Jo, Youngji; Jamieson, Lise; Edoka, Ijeoma; Long, Lawrence; Silal, Sheetal; Pulliam, Juliet R C; Moultrie, Harry; Sanne, Ian; Meyer-Rath, Gesine; Nichols, Brooke E
title: Cost-effectiveness of remdesivir and dexamethasone for COVID-19 treatment in South Africa
date: 2021-01-29
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab040
sha: 73f7694e0863b29d8755a6171a2e68423ee2db88
doc_id: 772722
cord_uid: 3eqrsk81

BACKGROUND: Dexamethasone and remdesivir have the potential to reduce COVID-related mortality or recovery time, but their cost-effectiveness in countries with limited intensive care resources is unknown. METHODS: We projected intensive care unit (ICU) needs and capacity from August 2020 to January 2021 using the South African National COVID-19 Epi Model. We assessed cost-effectiveness of 1) administration of dexamethasone to ventilated patients and remdesivir to non-ventilated patients, 2) dexamethasone alone to both non-ventilated and ventilated patients, 3) remdesivir to non-ventilated patients only, and 4) dexamethasone to ventilated patients only; all relative to a scenario of standard care. We estimated costs from the healthcare system perspective in 2020 USD, deaths averted, and the incremental cost effectiveness ratios of each scenario. RESULTS: Remdesivir for non-ventilated patients and dexamethasone for ventilated patients was estimated to result in 408 [uncertainty range: 229-1891] deaths averted (assuming no efficacy [uncertainty range: 0-70%] of remdesivir) compared to standard care, and save $15 million. The result was driven by the efficacy of dexamethasone, and the reduction of ICU-time required for patients treated with remdesivir. The scenario of dexamethasone alone to non-ventilated and ventilated patients requires additional $159,000 and averts 689 [uncertainty range: 330-1118] deaths, resulting in $231 per death averted, relative to standard care. CONCLUSIONS: The use of remdesivir for non-ventilated patients and dexamethasone for ventilated is likely to be cost-saving compared to standard care by reducing ICU days. Further efforts to improve recovery time with remdesivir and dexamethasone in ICU could save lives and costs in South Africa.

As of September 2020, there were over 29 million confirmed SARS-CoV-2 infections worldwide, and over 939,000 reported COVID-19 associated deaths. 1 South Africa has the 8th highest number of confirmed cases worldwide with more than 653,000 confirmed infections and 16,000 confirmed COVID-19 deaths. 2 During the surge in cases, intensive care unit (ICU) capacity was reportedly breached in some locations and much-needed oxygen supplies were running low. 3 While increased mortality is associated with several individual-level factors including older age, male sex, and preexisting comorbidities, systems-level factors such as being admitted to a hospital with fewer ICU beds also play a role. 4 Considering inter-hospital variation in treatment and outcomes, the mortality rate among those in ICU has ranged between 40%-50%. [4] [5] [6] To mitigate the mortality impact of COVID-19 in South Africa and other low-and middle-income countries with scant intensive care capacity, efforts to reduce mortality and duration of hospital stay amongst the more severe cases in ICU are paramount. Recently, two therapeutic agents, remdesivir and dexamethasone, have been demonstrated in randomized clinical trials to reduce COVID-related mortality and recovery time in ICU. 7, 8 Dexamethasone has been shown to decrease mortality by 35% (95% confidence interval [CI]: 18% to 49%) and 20% (95% CI: 8% to 30%) in ventilated ICU patients and non-ventilated patients with oxygen respectively and has shown no clear evidence regarding its impact on recovery time, 7 while remdesivir has been shown to reduce recovery time from 15 (95% CI: [13] [14] [15] [16] [17] [18] to 10 (95% CI: 9-11) days amongst ICU patients who are not ventilated 8 with no clear evidence regarding its impact on mortality. 9, 10 In low-and middle-income countries, not only is ICU capacity limited, but so are budgets for COVID-related care. There has been an additional budget allocation of $1.14 billion for the health response to COVID-19 in South Africa 11 , though this budget does not yet include remdesivir or dexamethasone. We therefore conducted a cost-effectiveness analysis to determine the incremental cost per death averted of providing dexamethasone and remdesivir relative to the standard care of critically ill patients in South African ICUs from a health systems perspective. The cost-effectiveness of these regimens is going to become increasingly important for possible eventuality of a COVID-19 resurgence in South Africa. Additionally, given the recent uncertainty in the clinical benefit of remdesivir, this analysis can further serve as a proxy for any intervention or treatment that reduces overall mortality, initiation of ventilation, and duration of hospital stay to determine cost-effectiveness up front.

In South Africa, there were a reported 3,318 public (1,178) and private (2,140) ICU beds available in total 14 and it was reported that only 70% (2,309 beds) were available for COVID patients as of 31 May 2020 12 . Using the South African National COVID-19 Epidemiology Model (NCEM) 13 and government data on the number of currently available ICU beds in the public and private sector by province 14 , we projected the number of people requiring ICU admission and total ICU person days by province by month between August 2020 and January 2021. (Appendix Table S1 -S2) We then projected costs and COVID-related mortality for four scenarios: 1) remdesivir to non-ventilated patients (i.e. to those receiving supplemental oxygen as in an earlier stage of disease illness) and dexamethasone administered to ventilated patients (i.e. in an advanced stage of disease illness), 2) M a n u s c r i p t 4 dexamethasone alone to both non-ventilated and ventilated patients, 3) remdesivir to nonventilated patients only, and 4) dexamethasone to ventilated patients only; all relative to standard of ICU care (without remdesivir and dexamethasone).

Our effectiveness measure was expressed as COVID-19 deaths averted. The mortality impact for all patients in ICU between August 2020 and January 2021 was estimated by applying the treatment impact of remdesivir and dexamethasone on mortality from the results of recent randomized controlled trials [7] [8] [9] and impact on mortality that remdesivir could have through decreasing the average length of stay of patients (from 15 to 10 days) 8 , when ICU capacity is expected to be breached (such that fewer people would die waiting for an ICU bed when those in the ICU are treated with remdesivir). Based on South African COVID-19 hospitalization data and treatment guidelines 15 , we assumed that 42% of patients in ICU require mechanical ventilation, while the remaining (58%) patients do not yet require mechanical ventilation (though they might require supplementary oxygen). A course of dexamethasone (oral/intravenous administration) is assumed to be 10 days long, and a course of remdesivir (intravenous) is assumed to be five days long. (Table 1) We estimated resource use from the perspective of the provider, the South African healthcare system, for all ICU-days accrued by COVID-19 patients from August 2020 and January 2021 for each scenario. Note that since COVID-19 patients will be accommodated in both the private and public sector, depending on need and availability, and contracting arrangements towards that end were in place in all provinces at the time of writing, we combined both sectors for the purpose of this analysis. We calculated health system operational cost (excluding drug costs) based on the latest NCEM outputs (i.e. required total ICU beds and days) with and without remdesivir and/or dexamethasone. We used an ICU cost per person day of $1,128 ($665-$1,172) based on an ingredients-based costing analysis including capital equipment, current South African ICU staffing norms and salaries, and overhead costs representative of South Africa public hospital settings. 16 Capital assets (e.g. ventilators) were annualized based on the relevant years of useful life (e.g. 10 years) and discounted at a 5% annual rate based on the South Africa pharmacoeconomic guidelines. 17 For the scenarios including novel therapeutics, we assumed the additional cost of a full course of remdesivir ($55 per 100mg IV, corresponding to $330 per patient course) 18 and/or dexamethasone ($3.13 per 4mg, corresponding to $31 per patient course) 19 , for the respective scenarios that include these therapeutics. (Table 2 ) Costs were converted from South African Rands (ZAR) to US dollars (USD) at the average exchange rate over the period August 2020 and January 2021 (1 USD = 16.95 ZAR). 20 Incremental cost effectiveness ratios were calculated as the incremental cost in 2020 USD of each therapeutic scenario over standard care per death averted .

We performed one-way and three-way sensitivity analyses on all model parameters to describe the robustness of the primary results expressed as incremental cost per death averted to uncertainty in individual model parameters. Parameters for the three-way sensitivity analysis were selected as the most influential parameters in one-way sensitivity analysis. Under our baseline assumptions, we also investigated whether and to what extent the benefit of a reduction in the length of ICU stay with remdesivir may differ by either assuming 1) capacity being breached for all months in all provinces versus 2) capacity never being breached. To explore the combined effect of uncertainty in our model M a n u s c r i p t 5 parameters, we conducted a probabilistic sensitivity analysis (PSA). All model parameter values were randomly sampled over pre-specified distributions (Table 2) and 1,000 simulations were performed to produce cost-effectiveness acceptability curves. The model was constructed in Microsoft Excel using an Excel Visual Basic Macro to run the simulations.

The estimated total health systems operation cost of COVID-19 related ICU care in South African excluding drugs during August 2020 and January 2021 is $83.9 million without remdesivir (standard care) and $68.3 million with remdesivir due to the reduction in required total ICU person days. In terms of drug costs, we estimated $995,000 required for remdesivir administered to non-ventilated patients, $67,000 for dexamethasone administered to ventilated patients, or $159,000 when dexamethasone is administered to all patients in the ICU across all six months. (Appendix Table S3) Overall, the scenario with a combination of remdesivir and dexamethasone can save $14.6 million relative to standard care and avert a total of 408 deaths (Table 3) . Of this, 26 deaths are averted due to remdesivir (by decreasing the average length of stay of patients when ICU capacity is expected to be breached), and 382 deaths averted due to dexamethasone on mortality. Similarly, the scenario of only remdesivir to non-ventilated patients can save $14.7 million relative to standard care due to a reduction in ICU-days, but will result in fewer total deaths averted (26) when assuming 0% reduction in mortality. The scenario with dexamethasone alone to ventilated and non-ventilated patients requires additional $159,000 but avert 689 deaths ($231 per death averted) relative to standard care. Therefore, as remdesivir becomes available and should it reduce recovery time in ICU, the use of remdesivir in combination with dexamethasone is recommended given the substantial cost savings and a similar health benefit.

Our one-way sensitivity analysis reveals that the uncertainty in the length of stay reduction by remdesivir, number of months ICU capacity is breached, efficacy of remdesivir and dexamethasone have the greatest impact on the ICER (Figure 1 ). The three-way sensitivity analysis (Figure 2 , Panel A) reveals that, assuming 0% remdesivir efficacy, if the ICU capacity is not expected to be breached at all, then the remdesivir and dexamethasone combination scenario can save up to $15 million (mainly due to the reduced total ICU days and health systems costs by remdesivir) and avert 383 deaths relative to standard care. But if ICU capacity is expected to be breached in all months and in all provinces, a scenario with remdesivir and dexamethasone combination will result in an additional drug costs of $12 million but will avert 10,394 deaths (5,773 from excess death and 4,621 from dexamethasone efficacy), resulting $1,141 per death averted relative to standard care. Even if remdesivir reduces mortality by 0% and only 1-day reduction in hospital stay, the scenario of remdesivir and dexamethasone combination will avert between 383 with $2 million cost saving and 5,446 deaths with $8.6 million cost increase ($1577 per death averted) by the zero to the full (6) months across all provinces of ICU capacity being breached, respectively.

The results of the PSA, displayed in the cost-effectiveness acceptability curves shows the probability of the intervention being cost-effective under different willingness to pay thresholds. We considered the threshold value as $3,015 per DALY averted in South Africa 21 which can be translated to $36,000 per death averted, assuming the average discounted life expectancy at time of COVID death in South M a n u s c r i p t 6 Africa to be 17 years (12 DALYs per death). As our findings show substantial cost-savings for the intervention including remdesivir, and a cost of less than $300 per death averted (uncertainty range $80-$647 per death averted) for the intervention of dexamethasone (Table 3) , these values fall far below any plausible threshold. For example, at a priori willingness to pay threshold of $1,000 per death averted, it is highly likely that the use of dexamethasone alone (to either both non-ventilated and ventilated patients or ventilated patients only) will be cost-effective (as shown almost 100% of simulation estimates fell below the threshold) compared to standard care in South Africa. (Appendix Figure S1 ) The scenarios that include remdesivir show almost 75% of simulations fall below the cost saving threshold (i.e. incremental cost is less than 0) with more variability, mainly due to the uncertainty around the reduced length of ICU stay that associated with high hospital costs per day.

This analysis explores whether and to what extent remdesivir and dexamethasone might be considered cost-effective for critically ill COVID-19 patients in South Africa. We find that the treatment with dexamethasone to non-ventilated and ventilated patients is expected to maximize the number of deaths averted (689) at incremental cost of $159,000 but treatment with remdesivir for non-ventilated patients and dexamethasone for ventilated patients can avert 408 deaths with substantial cost-savings of $15 million relative to standard care between August 2020 and January 2021 by reducing ICU days for the estimated COVID-19 patients being admitted in ICU. This costsavings would offset all of the remdesivir and dexamethasone-related costs, and the scenario including remdesivir also would help to alleviate already highly constrained ICU capacity. Despite great uncertainty in both efficacy and length of stay reduction for remdesivir 8-10 , our results could be applied to any drug or intervention that reduces the duration of ICU stay. An intervention or drug that costs the same or less then cost per ICU day (i.e. three times of the current remdesivir cost $330) and reduces the ICU stay just by one day could likely achieve cost-neutrality.

The results extend earlier findings regarding the mortality impact of remdesivir alone by reducing length of ICU stay and treating more COVID-19 patients in the ICU 13 which assumed the months during the first peak (June-August 2020) of COVID-19 epidemic in South Africa when resources were severely constrained. The number of deaths averted due to increasing ICU capacity in this analysis differ from our previous findings. 13 This is due to two factors. First, in this analysis we are assuming that only some patients in ICU receive remdesivir, instead of all patients. Second, the most recent set of model predictions from the NCEM project a waning epidemic in which ICU capacity is seldom breached. This has resulted in much fewer deaths averted projected due to increasing ICU capacity.

The cost-savings of remdesivir is mainly driven by the reduced length of ICU stay that associated with high hospital costs per day. The cost-savings, however, is also strongly influenced by the level and speed of epidemic control, varying from $15 million cost savings to a $12 million cost increase by the zero to the full (6) months across all provinces of ICU capacity being breached, respectively. The $12 million increase in cost is expected in a fully breached scenario given that all available COVID-related ICU days will be utilized during the full time period. Though a cost-increase would be expected in this scenario, there would be a reduction in mortality by increasing the number of people that can be treated in the ICU though a reduction in length of stay. (13) If ICU capacity is only breached in the first month (August) in the 9 provinces and no breach at all in the subsequent M a n u s c r i p t 7 months, the scenario of remdesivir and dexamethasone combined will result $4 million cost saving. If ICU capacity is however breached the first two months (from August and September) in all 9 provinces and no breach at all in the subsequent months, the scenario of remdesivir and dexamethasone combined costs an additional $2 million relative to standard care. Therefore, the duration of number of breached months directly corresponds to the level of cost-savings or expenditure that may be expected from the use of remdesivir and dexamethasone under a declining COVID-19 pandemic.

On the other hand, cost effectiveness of dexamethasone is mainly determined by the relationship between the drug cost and the efficacy. Since the drug cost is relatively low ($31), particularly as compared to remdesivir drug cost ($330) or hospital stay cost ($1,128) , the ICU specific parameters (i.e. cost per ICU stay, mortality rate of those in ICU) were instead greater influencers to the ICER for the scenario of dexamethasone for ventilated and non-ventilated patients. Dexamethasone has greater impact, however, on averting deaths (efficacy 35% to ventilated patients and 20% to nonventilated patients). If more severe patients enter into ICU, the cost-effectiveness of the dexamethasone scenario will continue to increase. Additionally, in the future, should dexamethasone also be shown to reduce the number of ICU days required, it is also likely to be considered cost-saving, as with many of our estimates for remdesivir.

Our analysis has several limitations. Firstly, the number of months ICU capacity is breached is influenced by the interplay between epidemic conditions and policy choices (which can affect ICU admission of other diseases). 22 As this will have different implications for costs and health outcomes in each scenario, it will be important to consider regional heterogeneity in epidemic conditions, health system capacity and willingness to pay in order to guide optimal treatment strategies in order to generalize our results. Second, we did not consider potential changes in the clinical course with disease progression nor change of distribution of disease severity among the patient population over time. Importantly, efficacy of remdesivir and dexamethasone in preventing mortality can be influenced by several factors -time of treatment initiation after symptom onset 23, 24 , age 25 , comorbidities 26 , potential adverse events 27 , and use of other medications 28, 29 . As additional treatment options become available 30 , it would also be important to collect more data on the duration of illness and its relationship to the outcome (both in terms of efficacy and safety) 27 and conduct more detailed analyses considering patient population characteristics, change of epidemic curves and local health system capacity, that can guide an optimal treatment strategy in a resource constrained setting. Third, our cost data does not include additional costs associated with adverse events management and also may not fully incorporate potential economies of scale due to increased volume of patients within a given ICU capacity. While the benefit of remdesivir in reduced length of ICU stay may not be limited to the ICU setting (and thus decrease overall societal costs), we did not include the implication into the cost analysis as it is beyond our analytic scope. We used a single unit cost for ICU patient-days based on a public sector costing analysis and did not differentiate costs or financial implication between public and private hospitals. While this may change the point estimate of our results, it is unlikely to alter our conclusions, and would only result in greater cost-savings/effectiveness of the interventions. Continued efforts to develop clinical practice guideline (i.e. who to treat, where, how and when) 31 to reduce length of ICU stay, for patients in ICU with COVID-19 32, 33 could further improve clinical benefits and cost-effectiveness. Finally, given that cost-savings observed with remdesivir is driven by months when ICU capacity is M a n u s c r i p t 8 not breached, the value for money of remdesivir may increase during the next phase of the pandemic as new cases decline and the pressure on ICUs eases. Given great uncertainty in making long-term projections into 2021, the time horizon for this study was limited to latest projections from the NCEM.

To conclude, our results show treatment with dexamethasone to non-ventilated and ventilated patients is expected to maximize the number of deaths averted, but treatment including remdesivir can be easily considered cost saving under a wide range of uncertainty through the reduction of ICU days for the COVID-19 patients being admitted in ICU. Despite great uncertainty in both efficacy and length of stay reduction for remdesivir, our results suggest that any intervention or drug that costs the same or less then cost per ICU day and reduces the ICU stay just by one day could likely achieve cost-neutrality. Cost-savings is also strongly influenced by the level and speed of epidemic control to avoid the ICU capacity being breached during a declining COVID-19 pandemic from the peak months. This analysis strongly supports treatment of COVID-19 patients in the ICU with dexamethasone and, should remdesivir improve recovery time, the treatment of early-stage ICU patients with remdesivir.

M a n u s c r i p t 9 M a n u s c r i p t 11 * Each scenario is compared to standard care. The number represents death averted by Remdesivir assuming 0% reduction in mortality. If we assume 30% reduction in mortality of Remdesivir, total number of deaths averted by the scenario 1: Dexamethasone to ventilated patients & Remdesivir to non-ventilated patients would be 882 (by averting 382 deaths by Dexamethasone and 500 deaths by Remdesivir due to decreasing the average length of stay of patients when ICU capacity is expected to be breached (474) and drug efficacy (26) . Accordingly, total number of deaths averted by the scenario 4: Remdesivir to nonventilated patients (58%) only would be 500.

Coronavirus Pandemic (COVID-19)

Oxygen already runs low as COVID-19 surges in South Africa

Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Remdesivir for the Treatment of Covid-19 -Final Report

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

The role of remdesivir in South Africa: preventing COVID-19 deaths through increasing ICU capacity

Estimating cases for COVID-19 in South Africa: Long-term national projections. South Africa: National Institute of Communicable Diseases; 2020. 15. National Institute for Communicable Disease. COVID-19 Guidelines

Inpatient Care Costs of COVID-19 in South Africa's Public Healthcare System. Under review. 17. Department of Health. Medicines and Related Substances Act (101/1965) Regulations relating to a transparent pricing system for medicines and scheduled substances: Publication of guidelines for pharmacoeconomic submissions. Pretoria: Government Gazette

OpenData South Africa. Essential medicine and master procurement catalogue

Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan

Optimal Targeted Lockdowns in a Multi-Group SIR Model.NBER Working Paper No. 27102

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. Drug Saf

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit

Coronavirus Drug and Treatment Tracker

COVID-19) Treatment Guidelines

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Remdesivir in adults with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial